Free Trial
NASDAQ:NGNE

Neurogene (NGNE) Stock Price, News & Analysis

$42.26
+0.84 (+2.03%)
(As of 04:32 PM ET)
Today's Range
$40.52
$43.09
50-Day Range
$30.32
$45.95
52-Week Range
$12.20
$53.00
Volume
72,695 shs
Average Volume
123,583 shs
Market Capitalization
$548.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.33

Neurogene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.11 Rating Score
Upside/​Downside
21.5% Upside
$51.33 Price Target
Short Interest
Bearish
9.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.88mentions of Neurogene in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.15) to ($4.07) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.39 out of 5 stars

Medical Sector

668th out of 896 stocks

Pharmaceutical Preparations Industry

317th out of 425 stocks

NGNE stock logo

About Neurogene Stock (NASDAQ:NGNE)

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

NGNE Stock Price History

NGNE Stock News Headlines

China Stockpiling Gold “Like No Tomorrow”
For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .
Neurogene to Participate in Upcoming Conferences
China Stockpiling Gold “Like No Tomorrow”
For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… .
Neurogene Inc. Q1 Loss Beats Estimates
Neurogene: Q1 Earnings Snapshot
See More Headlines
Receive NGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/10/2024
Today
7/19/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NGNE
Previous Symbol
NASDAQ:NGNE
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$51.33
High Stock Price Target
$65.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+21.5%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

Net Income
$-36,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$14.51 per share

Miscellaneous

Free Float
11,692,000
Market Cap
$548.53 million
Optionable
No Data
Beta
1.45
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Rachel L. McMinn Ph.D. (Age 51)
    Founder, Executive Chair & CEO
    Comp: $676.54k
  • Ms. Christine Mikail Cvijic J.D. (Age 46)
    President, CFO & Corporate Secretary
    Comp: $623.29k
  • Dr. Stuart Cobb Ph.D. (Age 54)
    Chief Scientific Officer
    Comp: $478.81k
  • Mr. Arvind Sreedharan
    Senior Vice President of Business Operations
  • Ms. Donna M. Cochener-Metcalfe J.D. (Age 49)
    Senior VP & General Counsel
  • Dr. Effie Albanis M.D.
    Senior Vice President of Early Clinical & Translational Research
  • Dr. Andrew E. Mulberg CPI
    FAAP, M.D., Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control
  • Mr. Ricardo Jimenez
    Senior Vice President of Technical Operations
  • Dr. Julie Jordan M.D. (Age 52)
    Chief Medical Officer

NGNE Stock Analysis - Frequently Asked Questions

How have NGNE shares performed this year?

Neurogene's stock was trading at $19.38 at the beginning of 2024. Since then, NGNE shares have increased by 118.1% and is now trading at $42.26.
View the best growth stocks for 2024 here
.

How were Neurogene's earnings last quarter?

Neurogene Inc. (NASDAQ:NGNE) issued its quarterly earnings data on Friday, May, 10th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.03) by $0.03.

How do I buy shares of Neurogene?

Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NGNE) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners